Search research articles
Contact Us
Filters
Showing results (191-200 of 377) with videos related to
Page
of 38
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2017
Preliminary results on response assessment using <sup>68</sup>Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 11, 2017
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber, Ken Herrmann, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 15, 2023
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
Robert Tauber, Karina Knorr, Margitta Retz, et al.
Radiology
|
December 9, 2025
Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET
Sungmin Woo, Benedetta Masci, Steven P Rowe, et al.
European Urology
|
June 10, 2022
Extensive <sup>177</sup>Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture
Hannah Schäfer, Sarah Mayr, Maike Büttner-Herold, et al.
EJNMMI Research
|
August 21, 2021
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
Hui Wang, Thomas Amiel, Christoph Würnschimmel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 7, 2022
Utility of <sup>18</sup>F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Thomas Langbein, Hui Wang, Isabel Rauscher, et al.
Physics and Imaging in Radiation Oncology
|
January 18, 2021
Multimodal imaging for radiation therapy planning in patients with primary prostate cancer
Constantinos Zamboglou, Matthias Eiber, Thomas R Fassbender, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 18, 2017
Detection Efficacy of Hybrid <sup>68</sup>Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, et al.
Molecular Imaging and Biology
|
May 22, 2010
Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer
Ambros J Beer, Matthias Eiber, Michael Souvatzoglou, et al.
Page
of 38
Search research articles
Search
Showing results (191-200 of 377) with videos related to
Sort By:
Page
of 38
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2017
Preliminary results on response assessment using <sup>68</sup>Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 11, 2017
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber, Ken Herrmann, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 15, 2023
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
Robert Tauber, Karina Knorr, Margitta Retz, et al.
Radiology
|
December 9, 2025
Navigating the Scoring Systems and Interpretation Frameworks of Prostate-specific Membrane Antigen PET
Sungmin Woo, Benedetta Masci, Steven P Rowe, et al.
European Urology
|
June 10, 2022
Extensive <sup>177</sup>Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture
Hannah Schäfer, Sarah Mayr, Maike Büttner-Herold, et al.
EJNMMI Research
|
August 21, 2021
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
Hui Wang, Thomas Amiel, Christoph Würnschimmel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 7, 2022
Utility of <sup>18</sup>F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Thomas Langbein, Hui Wang, Isabel Rauscher, et al.
Physics and Imaging in Radiation Oncology
|
January 18, 2021
Multimodal imaging for radiation therapy planning in patients with primary prostate cancer
Constantinos Zamboglou, Matthias Eiber, Thomas R Fassbender, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 18, 2017
Detection Efficacy of Hybrid <sup>68</sup>Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, et al.
Molecular Imaging and Biology
|
May 22, 2010
Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer
Ambros J Beer, Matthias Eiber, Michael Souvatzoglou, et al.
Page
of 38